Invasive pulmonary aspergillosis in patients with antineutrophil cytoplasmic antibody associated vasculitis

Journal of Clinical Rheumatology

Volumn 15, Issue 8, 2009, Pages 380-382

  Su, Tao ^a,b,c   Li, Hai Chao ^a   Chen, Min ^a,b,c   Gao, Li ^a   Zhou, Fu De ^a,b,c   Wang, Ren Gui ^a   Zhang, Hong ^a,b,c   Li, Xiao Mei ^a,b,c   Zhao, Ming Hui ^a,b,c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

ANCA; Invasive pulmonary aspergillosis; Mortality; Vasculitis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOPHOSPHAMIDE; HEMOGLOBIN; ITRACONAZOLE; METHYLPREDNISOLONE; PREDNISONE;

AGED; ANCA ASSOCIATED VASCULITIS; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE COURSE; FEMALE; GLOMERULONEPHRITIS; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG ASPERGILLOSIS; LUNG HEMORRHAGE; LUNG INJURY; MALE; MICROSCOPIC POLYANGIITIS; MULTIPLE ORGAN FAILURE; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; WEGENER GRANULOMATOSIS;

AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIFUNGAL AGENTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 74549142596     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31819e67b1     Document Type: Article

References (20)

1. Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in hematopoietic stem cell transplant recipients. Br J Haematol. 2007;139:519-531.
2. Trof RJ, Beishuizen A, Debets-Ossenkopp YJ, et al. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007;33:1694-1703.
3. Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically Ill patients without malignancy. Am J Respir Crit Care Med. 2004;15:170:621-625.
4. Vaideeswar P, Prasad S, Deshpande JR, et al. Invasive pulmonary aspergillosis: a study of 39 cases at autopsy. J Postgrad Med. 2004;50:21-26.
5. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-917.
6. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;3:827-833. (Pubitemid 36917771)
7. Chen M, Yu F, Zhang Y, et al. Clinical and pathological characteristics of Chinese patients with anti-neutrophil cytoplasmic autoantibodies associated systemic vasculitides: a study of 426 patients from a single center. Postgrad Med J. 2005;81:723-727.
8. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century-a disease of older patients. Rheumatology. 2005;44: 495-501.
9. Yu F, Chen M, Zhao MH, et al. Analysis of the causes of death in patients with ANCA associated systemic vasculitis. Beijing Med J. 2007;4:196-200.
10. Akimoto T, Saito O, Inoue M, et al. Rapid formation of Aspergillus mycetoma in a patient receiving corticosteroid treatment. Serial radiographic observation over two months. Intern Med. 2007;46:733-737.
11. Vahid B, Wildemore B, Nguyen C, et al. Positive C-ANCA and cavitary lung lesion: recurrence of Wegener granulomatosis or aspergillosis? South Med J. 2006;99:753-756.
12. Jennette JC, Falk R, Andrassy K, et al. Nomenclature of systemic vasculities: proposal of an international consensus conference. Arthritis Rheum. 1994;37: 187-192.
13. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
14. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-678.
15. Knaus WA, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
16. Available at: http://www.aspergillus.org.uk/.
17. Segal BH. Role of macrophages in host defense against aspergillosis and strategies for immune augmentation. Oncologist. 2007;12(suppl 2):7-13.
18. Zhang N, Truong-Tran QA, Tancowny B, et al. Glucocorticoids enhance or spare innate immunity: effects in airway epithelium are mediated by CCAAT/ enhancer binding proteins. J Immunol. 2007;179:578-589.
19. Palmer LB, Greenberg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease. Thorax. 1991;46:15-20.
20. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67:1567-1601.